期刊
JOURNAL OF CELL BIOLOGY
卷 200, 期 2, 页码 187-202出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1083/jcb.201204053
关键词
-
类别
资金
- National Institute of General Medical Sciences [RO1 GM094513-01]
- Department of Defense Breast Cancer Research Program [BC110089]
- Siteman Cancer Center
- American Heart Association
- National Cancer Institute [R01CA154625]
- Beca Marta Santamaria
- programa de intensificacion de la investigacion
- Instituto Carlos III
- Barnes Jewish Hospital Auxilary
- [2009SGR794]
- [RD06/0020/1034]
Loss of 53BP1 rescues BRCA1 deficiency and is associated with BRCA1-deficient and triple-negative breast cancers (TNBC) and with resistance to genotoxic drugs. The mechanisms responsible for decreased 53BP1 transcript and protein levels in tumors remain unknown. Here, we demonstrate that BRCA1 loss activates cathepsin L (CTSL)-mediated degradation of 53BP1. Activation of this pathway rescued homologous recombination repair and allowed BRCA1-deficient cells to bypass growth arrest. Importantly, depletion or inhibition of CTSL with vitamin D or specific inhibitors stabilized 53BP1 and increased genomic instability in response to radiation and poly(adenosine diphosphate-ribose) polymerase inhibitors, compromising proliferation. Analysis of human breast tumors identified nuclear CTSL as a positive biomarker for TNBC, which correlated inversely with 53BP1. Importantly, nuclear levels of CTSL, vitamin D receptor, and 53BP1 emerged as a novel triple biomarker signature for stratification of patients with BRCA1-mutated tumors and TNBC, with potential predictive value for drug response. We identify here a novel pathway with prospective relevance for diagnosis and customization of breast cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据